Inovio Pharmaceuticals, Inc. (INO): Capital Expenditures
$285.7K
Year ended 2025-12-31
$195.4K
Trailing 12 months to 2026-06-30
-33.4%
3-year compound annual growth
-28.4%
5-year compound annual growth
-20.4%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $285.7K | -41.4% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $487.8K | +52.0% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $320.9K | -66.9% | 2025-03-18, From 2023-01-01 |
| 2022-12-31 | $969.2K | -21.3% | 2024-03-06, From 2022-01-01 |
| 2021-12-31 | $1.23M | -19.0% | 2024-03-06, From 2021-01-01 |
| 2020-12-31 | $1.52M | +53.9% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $987.9K | -52.6% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $2.09M | -79.7% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $10.29M | +275.9% | 2020-03-12, From 2017-01-01 |
| 2016-12-31 | $2.74M | -1.5% | 2019-03-12, From 2016-01-01 |
| 2015-12-31 | $2.78M | +101.6% | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $1.38M | +680.0% | 2017-03-15, From 2014-01-01 |
| 2013-12-31 | $176.9K | -26.6% | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | $241.0K | +49.5% | 2015-03-16, From 2012-01-01 |
| 2011-12-31 | $161.2K | -11.3% | 2014-03-17, From 2011-01-01 |
| 2010-12-31 | $181.6K | +275.6% | 2013-03-18, From 2010-01-01 |
| 2009-12-31 | $48.4K | n/a | 2012-03-15, From 2009-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Inovio Pharmaceuticals, Inc. (INO) | 2025-12-31 | $285.7K | -41.4% |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | $434.0K | -42.1% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $0 | -100.0% |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $8.0K | -97.1% |
| Actinium Pharmaceuticals, Inc. (ATNM) | 2025-12-31 | $104.0K | +845.5% |
| iBio, Inc. (IBIO) | 2026-06-30 | $578.0K | n/m |
| Altimmune, Inc. (ALT) | 2025-12-31 | $11.0K | n/a |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $500.0K | n/a |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $780.0K | +68.1% |
Compare INO, CNTB, HCWB, IXHL side by side · Screen every company in Pharmaceutical Preparations ↗